Citi analyst Geoff Meacham raised the firm’s price target on Kiniksa (KNSA) to $50 from $45 and keeps a Buy rating on the shares as part of a Q3 preview for the biotechnology group. The firm believes investor interest in the smaller cap biotech names is building, which could set the group up well for 2026.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KNSA:
- Kiniksa granted orphan designation for treatment of pericarditis
- Kiniksa price target raised to $44 from $38 at Wedbush
- Kiniksa Pharmaceuticals: Strong Buy Rating Driven by Arcalyst’s Market Success and Promising Pipeline
- Kiniksa initiated with a Buy at TD Cowen
- Kiniksa Pharmaceuticals Highlights Cardiovascular Focus and Growth